Mazzone Awards Program Funding Recipients

Table of Contents

2013

Career Development Recipients
Impact on Prognosis of Inter- and Intratumor Heterogeneity In Prostate Cancer
PI: Jennifer Sinnott, PhD
Mentors: Lorelei Mucci, ScD (HSPH), Giovanni Parmigiani, PhD (DFCI)
Collaborators: Massimo Loda, MD (DFCI), Kathryn Penney, ScD (BWH) 

Community Outreach
Shared Medical Appointments: An Innovative Approach to Prostate Cancer Survivorship Care

PI: Larissa Nekhlyudov, MD, MPH (Harvard Vanguard Medical Associates)
Collaborators: Ann Partridge, MD, MPH (DFCI); Wilmer Roberts, MD, PhD (Harvard Vanguard Medical Associates); Michael Pistiner, MD, MMSc (Harvard Vanguard Medical Associates); Aymen Elfiky, MD, MPH (DFCI); Christopher Recklitis, PhD, MPH (DFCI); Sarah Reed, MPH, MSW (DFCI)

Disparities Research
Chronic stress and racial disparities in prostate cancer

PI: Lisa Signorello, ScD (HSPH)
Collaborators: Jennifer Rider, ScD (HSPH); Sebastien Haneuse, PhD (HSPH); Unnur Valdimarsdottir, PhD (University of Iceland)

High Impact Projects
Co-targeting AR and ERG to treat advanced prostate cancer
PI: Karen Knudsen, PhD (Thomas Jefferson University)
Co-PIs: Felix Feng, MD (University of Michigan); Myles Brown, MD (DFCI)

Genome-wide analysis of response to androgen deprivation therapy
PI: Mark Pomerantz, MD (DFCI)
Collaborators: Matthew Freedman, MD (DFCI); Christopher Sweeney, MBBS (DFCI); Manish Kohli, MBBS (Mayo Clinic); Svitlana Tyekucheva, PhD (DFCI) 

Targeting Androgen Receptor Pathway-Independent Prostate Cancer (APIPC)
PI: Peter Nelson, MD (Fred Hutchinson Cancer Research Center)
Co-PI: Marc Vidal, PhD (DFCI)
Collaborator: Muneesh Tewari, MD, PhD (Fred Hutchinson Cancer Research Center) 

High Impact Clinical Trials
Clinical Trials Assessing Mechanisms Mediating Sensitivity and Resistance to Enzalutamide
PI: Mary-Ellen Taplin, MD (DFCI)
Co-PIs: Bruce Montgomery, MD (University of Washington); Elahe Mostaghel, MD, PhD (Fred Hutchinson Cancer Research Center); Xin Yuan, MD, DSc (BIDMC)
Collaborators: Steven Balk, MD, PhD (BIDMC); Glenn Bubley, MD (BIDMC); Mark Pomerantz, MD (DFCI); Colm Morrissey, PhD (University of Washington)

Project Development
Developing Novel Targeted Therapies for Advanced Prostate Cancer
PI: Karen Cichowski, PhD (BWH)

Targeting the Co-Activator Site on the Androgen Receptor
PI: Gregory Verdine, BS, PhD (Harvard University, Chemistry Department)
Collaborator: Levi Garraway, MD (DFCI)

Project Funded through the Prostate Cancer Foundation Mazzone Challenge Award
Synergistic Immune and lipid Metabolism Targeting for Metastatic Prostate Cancer Therapy
PI: Jennifer Wu, PhD, (Medical University of South Carolina)
Co-PIs: James S. Norris, PhD (Medical University of South Carolina); Michael Lilly, MD (Medical University of South Carolina); Xiang Liu, MD, PhD (Medical University of South Carolina); Ali Goshayan, MD (Medical University of South Carolina)
Collaborators: Richard Drake, PhD (Medical University of South Carolina); Ann-Marie Broome, PhD (Medical University of South Carolina); Elizabeth Garrett-Mayer, PhD (Medical University of South Carolina)

[back]

 

2012

High Impact Mazzone Awards Recipients
Molecular Characterization Of Gleason 3 Tumors That Progress To Gleason 4
PI: Steven Balk, (Beth Israel Deaconess Medical Center)
Collaborator: Wei Li (Baylor College of Medicine)

Defining the spectrum of resistance to androgen ablation therapy in prostate cancer
PI: Levi Garraway (Dana-Farber Cancer Institute)
Collaborators: William Hahn (Dana-Farber Cancer Institute), Mark Rubin (Weill Cornell Medical College)

Project Development Mazzone Awards Recipients
Castration-Resistant Luminal Cells in the Prostate
PI: Zhe Li (BWH)
Collaborator: Stuart Orkin (Children’s Hospital Boston)

Developing a Blood-based Metabolomic Signature of Gleason Score
PI: Massimo Loda (DFCI)
Collaborators: Kathryn Penney (Brigham and Women's Hospital), Svitlana Tyekucheva (Harvard School of Public Health)

Nanoplatforms for Localized Chemo Radiation Therapy for Prostate Cancer
PI: Robert Cormack (DFCI)
Collaborators: Anthony D’Amico (Dana-Farber Cancer Institute), Alec Kimmelman (Dana-Farber Cancer Institute), Mike Makrigiorgos (Dana-Farber Cancer Institute), Srinivas Sridhar (Northeastern University)

Disparities Research Mazzone Awards Recipients
Estimating The Prostate Cancer Burden Attributed To Lifestyle And Genetic Factors Among African-American And White Men
PI: Lorelei Mucci (Harvard School of Public Health)
Collaborators: Edward Giovannucci (Harvard School of Public Health), Massimo Loda (Dana-Farber Cancer Institute), Lisa Signorello (Vanderbilt University)

Factors Influencing Willingness To Participate In Biobanking Among Black Men With And At-Risk For Prostate Cancer
PI: Karen Emmons (Dana-Farber Cancer Institute)
Collaborators: Laura Hayman (University of Massachusetts Boston), J Jacques Carter (Beth Israel Deaconess Medical Center, Aymen Elfiky (Dana-Farber Cancer Institute), Christopher Lathan (Dana-Farber Cancer Institute)

Career Development Mazzone Awards Recipients
Within-Person Molecular Differences in Primary Versus Metastatic Prostate Cancer
PI: Julie Kasperzyk (Brigham and Women’s Hospital)
Collaborators: Steven Balk (Beth Israel Deaconess Medical Center), Giovanni Parmigiani (Harvard School of Public Health, Meir Stampfer (Brigham and Women’s Hospital)

PI: Jennifer Rider (Harvard School of Public Health)
Collaborators: Lorelei Mucci (Harvard School of Public Health), Giovanni Parmigiani (Dana-Farber Cancer Institute), Christopher Sweeney (Dana-Farber Cancer Institute), Michelangelo Fiorentino (Harvard School of Public Health), Ove Andren (University of Orebro)

Lupron-Treatable Diseases and Conditions Mazzone Awards Recipients
Targeting estrogen-dependent mechanisms in lymphangioleiomyomatosis (LAM) 
PI: Elizabeth Henske, MD (Brigham and Women’s Hospital) 
Collaborator: Jane Yu, PhD (Brigham and Women’s Hospital)

Pre-clinical in vivo studies investigating the efficacy of mTOR inhibitors for uterine fibroids
PI: Jose Teixeira, PhD (Massachusetts General Hospital) 
Collaborator: Bradley Quade, MD (Brigham and Women’s Hospital)

Prostate Cancer Foundation Mazzone Awards Recipients
Promoter-Driven Molecular Radiotherapy for Prostate Cancer
PI: Martin Pomper, MD, PhD (Johns Hopkins Medicine)
Collaborators: George Sgouros, PhD (Johns Hopkins Medicine); Paul Fisher, PhD (Virginia Commonwealth University).

Targeting the p160 Steroid Receptor Coactivators (SRCs) as a Novel Approach for the Treatment of Castration-Resistant Prostate Cancer

PI: Bert O’Malley, MD (Baylor College of Medicine)
Collaborators: Nancy Weigel, PhD; Ming-Jer Tsai, PhD; Francesco DeMayo, PhD; Michael Ittman, MD, PhD; Nicholas Mitsiades, MD, PhD; Sean McGuire, MD, PhD, (Baylor College of Medicine)

Community Outreach Mazzone Awards Recipients
Engaging African American Faith Communities in Prostate Cancer Education
PI: Jennifer Allen (Dana-Farber Cancer Institute)
Collaborator: Donna Berry (Dana-Farber Cancer Institute)

[back]

 

2011

High Impact Mazzone Awards Recipients
Functional Annotation of Prostate Cancer Risk Loci Discovered through Genome Wide Association Studies
PI: Matthew Freedman, MD (DFCI)
Collaborator: Gerhard Coetzee, PhD (USC/Norris Cancer Center - Keck School of Medicine)

Project Development Mazzone Awards Recipients
Epigenetic Reprogramming of AR Function in CRPC
PI: Myles Brown, MD. (Dana-Farber Cancer Institute)

Pharmacological validation of Etk/BMX as a target for the treatment of prostate cancer
PI: Nathanael Gray, PhD. (Dana-Farber Cancer Institute)
Collaborator: Steven Balk, MD, PhD (Beth Israel Deaconess Medical Center)

Cancer Stem Cells Targeting in Castration Resistant Prostate Cancer
PI: Pier Paolo Pandolfi, MD., PhD (Beth Israel Deaconess Medical Center)

DNase-seq for Cost-effective Identification of Functional Mutations in Prostate Cancers
PI: Xiaole Shirley Liu, PhD (Dana-Farber Cancer Institute)
Collaborators: Myles Brown, MD (Dana-Farber Cancer Institute) Levi Garraway, MD, PhD (Dana-Farber Cancer Institute) Soumya Raychaudhuri, MD, PhD (Harvard Medical School)

Disparities Research Mazzone Awards Recipients
Enhancing Usability of the Personal Patient Profile-Prostate (P3P) for Black and Hispanic Men
PI: Donna Berry, PhD, RN (Dana-Farber Cancer Institute)
Collaborators: Julia Hayes, MD (Dana-Farber Cancer Institute) Martin Sanda, MD (Beth Israel Deaconess Medical Center) Seth Wolpin, PhD, MPH, RN (University of Washington)

Understanding Racial Differences in Prostate Cancer Mortality
PI: Nancy Keating, MD, MPH (Harvard Medical School)
Collaborators: Glen Taksler, PhD (New York University) David Cutler PhD (Harvard University School of Economics)

Career Development Mazzone Awards Recipients
Probing androgen receptor signaling in circulating tumor cells in prostate cancer
PI: David Miyamoto, MD, PhD (Massachusetts General Hospital)
Collaborator: Daniel Haber, MD, PhD (Massachusetts General Hospital)

Prostate cancer genetic variants, molecular alterations and mRNA expression
PI: Kathryn Penney, ScD, BA (Brigham and Women’s Hospital)
Collaborator: Massimo Loda, MD (Brigham and Women’s Hospital)

Phosphorus and calcium intake, tumor microenvironment and prostate cancer progression
PI: Kathryn Wilson, Sc.D. (Harvard School of Public Health)
Collaborators: Lorelei Mucci, MPH, ScD (Brigham and Women’s Hospital), Edward Giovannucci, MD, ScD (Harvard School of Public Health), Michelangelo Fiorentino, MD, PhD (Harvard School of Public Health)

Lupron-Treatable Diseases and Conditions Mazzone Awards Recipients
Cancer and Endometriosis
PI: Stacey Missmer, ScD (Brigham and Women’s Hospital)
Collaborators: Rulla Tamimi, ScD (Brigham and Women’s Hospital); Jiali Han__, (Brigham and Women’s Hospital)

Prostate Cancer Foundation Mazzone Awards Recipients
Imaging Biomarkers of Treatment Response Using NaF PET/CT Imaging: a Prostate Cancer Clinical Trials Consortium (PCCTC) Effort
PI: Glenn Liu, MD (UW Carbone Cancer Center)
Collaborators: Michael Morris, MD (Memorial Sloan-Kettering Cancer Center); William Dahut, MD (National Cancer Institute); Steven Larson, MD (Memorial Sloan-Kettering Cancer Center); Peter Choyke, MD (National Cancer Institute); Robert Jeraj, PhD, (UW Carbone Cancer Center)

Induction of Synthetic Lethality with Epigenetic therapy (ISLET) for Systemic Treatment of Prostate Cancer
PI: William G. Nelson, MD, PhD (Johns Hopkins Medicine)
Collaborators: Srinivasan Yegnasubramanian, MD, PhD (Johns Hopkins Medicine); Jun O. Liu, PhD, (Johns Hopkins Medicine); Stephen B. Baylin, MD (Johns Hopkins Medicine); Michael A. Carducci, MD (Johns Hopkins Medicine); Martin J. Aryee, PhD (Johns Hopkins Medicine)

[back]